PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities

Episodes 1-3 of 3

• 

  RestartResume

  A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

  RestartResume

  A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

  ESC 2016

  A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

  • 

    

    Paul M Ridker, MD

• 

  RestartResume

  Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

  RestartResume

  Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

  ESC 2016

  Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

  • 

    

    John Kastelein, MD

• 

  RestartResume

  PCSK9, the short track road from discovery as drug target towards the clinic

  RestartResume

  PCSK9, the short track road from discovery as drug target towards the clinic

  ESC 2016

  PCSK9, the short track road from discovery as drug target towards the clinic

  • 

    

    Gilles Lambert, MD